Medibio Corporate Health Extends Global Footprint Signing Contract with Jacobs Engineering
Jacobs, one of the world's largest engineering and environmental consultancy groups, has more than 70,000 employees globally
SYDNEY, Australia and MINNEAPOLIS, May 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced a significant contract for Medibio's Corporate Health product with Dallas, TX-based Jacobs Engineering across their Asia Pacific, Middle East, and European divisions.
Through the Mental Health Check-In, companies can offer employees an end-to-end mental health program, direct to their devices, to see how the mind and body are tracking. It's a personalized, private, and objective way to see the unseeable: mental health issues in the workplace.
Employees are provided the opportunity to confidentially check-in on their mental health and receive personalized confidential results from both an objective biometric screening in conjunction with a 12-minute subjective survey. Employers receive a dashboard providing de-identified, amalgamated data on the well-being of their workforce leveraging both the subjective and objective metrics. Employees then have the option to connect their wearable devices, such as Apple Watch, Garmin, and Fitbit, collect heart rate and sleep data.
The first-phase contract extends Medibio's engagement with Jacob's beyond Asia Pacific, to now encompass over 8,000 employees across Asia Pacific, India, the Middle East and Europe. The Check-In will be rolled out to Jacobs' European leadership team alongside the Asia Pacific and Middle Eastern workforces and is projected to generate first-stage revenue of approximately $50,000 for the initial four-week program. Services, including consultancy and delivery of ongoing mental health interventions and programs, will be billed as provided.
The correlation of ANS biometrics and mental health has been the focus of the company for over 20 years. Especially while sleeping, our bodies reflect our mental state through the performance of the autonomic nervous system. Medibio's technology platform detects dysfunction within the areas of the body regulated by the ANS, and through proprietary data processing and algorithms, the technology correlates these anomalies to different mental health conditions. It is a profound discovery that for the first time provides a tangible, objective understanding of mental health.
"We are thrilled to extend our pivotal agreement with Jacobs Engineering, a long-term supporter of Medibio and a leading corporation in driving the way mental health care is delivered to their employee base," said CEO and Managing Director Jack Cosentino. "By leveraging our proprietary technology, in conjunction with Jacobs' strong corporate advocacy, we look forward to establishing a long-term relationship to enable real change in the area of corporate mental health."
Jacobs Engineering Group is one of the world's largest engineering and environmental consultancy groups. With a reputation for innovation, performance, and a human centric approach to employment and consultancy they have sought out programs that align with their values and integrate with their culture. Jacobs currently employs over 70,000 employees in over 250 offices worldwide.
Patrick Hill, Sr. Vice President and General Manager Buildings, Infrastructure and Advanced Facilities at Jacobs said: "Our partnership with Medibio appears to have been hugely beneficial to date. Their analytical and evidence-based approach is a significant step forward for an organization like Jacobs that is looking to move from awareness to action, and from reaction to prevention. As a company that aims to puts its people first, we are delighted to be extending the Check-in to other parts of our global business."
This contract signed by Jacobs Engineering continues Medibio's rapidly expanding portfolio of global companies participating in the Mental Health Check-in including:
- Jacobs Engineering (U.S.)
- St. John of God Health Care (Australia's third-largest healthcare provider)
- Australian Football League (AFL)
- Rio Tinto
- Aurecon Jacobs Joint Venture for West Gate Tunnel Project
The Mental Health Check-in Campaign is the entry-level offering to Medibio's Corporate Health products and is rapidly positioning Medibio as the preeminent mental health technology and services provider offering comprehensive mental health solutions for businesses.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Jacobs leads the global professional services sector delivering solutions for a more connected, sustainable world. With $15 billion in fiscal 2017 revenue when combined with full-year CH2M revenues and a talent force of more than 77,000, Jacobs provides a full spectrum of services including scientific, technical, professional and construction- and program-management for business, industrial, commercial, government and infrastructure sectors. For more information, visit www.jacobs.com, and connect with Jacobs on LinkedIn, Twitter, Facebook and Instagram.
|Further Information:||Website: www.medibio.com.au|
T: 952-222-0551 ext. 208
T: +61 434 405 400
A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dca9e5bd-b9a4-4500-9840-9530068038c8
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial4.6.2020 19:10:28 CEST | Press release
Bagsværd, Denmark, 4 June 2020 – Novo Nordisk today announced headline results from STEP 1, a phase 3a trial in the STEP programme. STEP 1 is a 68-week randomised, double-blind, multicentre, placebo-controlled weight management trial. The trial investigated the efficacy and safety of once-weekly subcutaneous (sc) semaglutide 2.4 mg on body weight over 68 weeks compared to placebo in 1,961 adults with obesity or overweight with comorbidities, both in conjunction with lifestyle intervention. The STEP 1 trial met both primary endpoints. In all people randomised1, a statistically significant and superior reduction in body weight was achieved with sc semaglutide 2.4 mg compared to placebo after 68 weeks. People treated with sc semaglutide 2.4 mg achieved a weight loss of 14.9%, from a mean baseline body weight of 105.3 kg, compared to a 2.4% weight loss with placebo. In addition, 86.4% of those who received sc semaglutide 2.4 mg reached a weight loss of 5% or more after 68 weeks, compared t
Scandinavian Tobacco Group A/S: Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities4.6.2020 18:00:00 CEST | Press release
Company Announcement No. 15/2020 Copenhagen, 4 June 2020 Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Claus Gregersen 2. Reason for the notification a) Position/title Member of the Board of Directors b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Purchase of shares c) Price(s) and volume(s) Price(s)Volume(s)98.8
Scandinavian Tobacco Group A/S: Indberetning og offentliggørelse af transaktioner udført af person med ledelsesansvar4.6.2020 18:00:00 CEST | pressemeddelelse
Selskabsmeddelelse Nr. 15/2020 København, den 4. juni 2020 Indberetning og offentliggørelse af transaktioner udført af person med ledelsesansvar 1. Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne a) Navn Claus Gregersen 2. Årsag til indberetningen a) Stilling/titel Medlem af bestyrelsen b) Første indberetning/ændring Første indberetning 3. Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførende a) Navn Scandinavian Tobacco Group A/S b) LEI-kode 5299003KG4JS99TRML67 4. Nærmere oplysninger om transaktionen/transaktionerne: gentages for (i) hver type instrument, (ii) hver type transaktion, (iii) hver dato og (iv) hvert sted, hvor der er udført transaktioner a) Beskrivelse af det finansielle instrument, instrumenttypen Identifikationskode Aktier DK0060696300 – STG b) Transaktionens art Køb af aktier c) Pris(er) og mængde(r) Pris(er)Mængde(r)98,8849 aktier98
Maha Energy AB (publ) Announce May Production Volumes4.6.2020 17:00:00 CEST | Press release
Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm June 4, 2020 Maha Energy AB (publ) Announce May Production Volumes Production Volumes The Company's aggregate sales production for the month of May totaled 106,2481 barrels of oil and 52.765 million scf of gas for a combined average production of approximately 3,711 BOE/day2, before royalties and taxes. The month of May saw increasing gas sales at Tie as a new gas end-user started taking deliveries allowing for higher oil production. Further at both Tie and Tartaruga stations, oil production was somewhat affected due to temporary surface jet pump maintenance issues which were resolved during the month. Despite the pump issues and continuing Covid-19 movement restrictions, production and off-take volumes in Brazil remain stable. 1 Subject to minor standard industry adjustments at the time of custody transfer. 2 Barrels of oil equivalent ("BOE") conversion ratio of 6,000 scf: 1 bbl is us
Cyber Security 1 AB: CYBER1 Confirms Publication Date for the 2019 Annual Report4.6.2020 16:45:00 CEST | Press release
CYBER1 Confirms Publication Date for the 2019 Annual Report London United Kingdom – 04 June 2020, Cyber Security 1 AB (Publ) (“CYBER1”), (Nasdaq:CYB1, OTCQX:CYBNY), has announced a revised publication date of the 9th of June, for the 2019 Annual Report. The change in date brings the 2019 Annual Report publication in line with the Cyber Security 1 AB 2020 AGM, scheduled for Tuesday, 30 June 2020. Shareholders and key stakeholders in the interim may refer to the full year unaudited accounts, through the Q4 2019 report available on our website: www.cyber1.com The annual report once published will be available to view on the CYBER1 website. Certified Adviser Mangold Fondkommission AB is the Company’s Certified Adviser. Telephone: +46 (0)8 5030 1550 E-mail: firstname.lastname@example.org FOR FURTHER INFORMATION, PLEASE CONTACT: Investor Relations Contact: Tim Metcalfe / Zach Cohen CYBER1 Email: email@example.com ABOUT CYBER1 CYBER1 is engaged in providing cyber resilience solutions and conducts it
Auction details Inflation-linked bonds4.6.2020 16:20:00 CEST | Press release
Auction date June 11, 2020 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2027-12-01 3113SE0009548704 0.125% 750 2032-06-01 3111 SE0007045745 0.125% 250 Settlement date June 15, 2020 Bids have to be entered by 11.00 on June 11, 2020 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 firstname.lastname@example.org